{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MIB in systolic BP >=40 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MDB in systolic BP <=-60 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MIB in diastolic BP >=20 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MDB in diastolic BP >-40 and <=-20mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MDB in diastolic BP <=-40 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"Maximum post baseline pulse rate >130 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"Minimum post baseline pulse rate <50 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MIB in pulse rate >=30 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MDB in pulse rate <=-30 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MIB in body weight >=10%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"MDB in body weight <=-10%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"Criteria for vital signs abnormalities: postbaseline pulse rate less than (\\<) 50 beats per minute (bpm) or greater than (\\>)130 bpm and maximum increase from baseline in pulse rate \\>=30 bpm and maximum decrease from baseline in pulse rate \\<=30 bpm. Systolic blood pressure (BP) of maximum increase from baseline (MIB) \\>=40 millimeters of mercury (mmHg), maximum decrease from baseline (MDB) in systolic blood pressure =\\<60 mmHg. Diastolic blood pressure of MIB \\>=20 mmHg and MDB in diastolic blood pressure \\>-40 and =\\<-20 mm Hg. And MDB in diastolic BP\\<=-40 mmHg. Only categories with at least 1 participant with abnormality are reported in this outcome measure.","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"},{"description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG001","title":"Gefitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization until death or last date known as alive, up to 61 months","title":"Number of Participants With Clinically Significant Abnormalities in Vital Signs","type":"SECONDARY","unitOfMeasure":"Participants"}